Cullinan Therapeutics Presents Preclinical Data for CLN-978
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) shared additional preclinical data for CLN-978, a novel CD19xCD3 bispecific T cell engager, at ACR Convergence 2025.
CLN-978 demonstrated rapid and deep B cell depletion in vitro and in vivo across multiple autoimmune diseases.
- Presenter: Cullinan Therapeutics, Inc.
- Event: American College of Rheumatology (ACR) Convergence 2025
- Location: Chicago, Illinois
- Date: October 24-29
- Poster Session: October 28, 10:30 a.m.-12:30 p.m. CT (Poster Session C, Poster Number 2293)
CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases
Cullinan Therapeutics will also have a booth (#1074) in the Exhibit Hall.
Author's summary: Cullinan Therapeutics presents preclinical data for CLN-978.